Organoids for the development of drugs and diagnostics for NASH
Organoids at different stages of non-alcoholic steatohepatitis (NASH) progression have been created to help in drug design and identification of diagnostic biomarkers.
List view / Grid view
Organoids at different stages of non-alcoholic steatohepatitis (NASH) progression have been created to help in drug design and identification of diagnostic biomarkers.
Researchers have developed a vaccine against the COVID-19 coronavirus which induced the rapid production of antibodies in mice.
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
Researchers have created an accurate mouse model of Duchenne muscular dystrophy (DMD), showing that TGFβ is a potential target for the condition.
The University of Alabama at Birmingham (UAB) will run the pre-clinical trials of Altimmune’s intranasal COVID-19 vaccine candidate, AdCOVID.
A collaboration aims to utilise a compound library of 15,000 clinically-ready molecules and screen then against three COVID-19 targets.
Researchers have developed a new CAR T-cell therapy that targets an antigen called glycipan-1 (GPC1), showing efficacy at fighting solid tumours in mice.
Researchers captured 13,000 images of a mouse norovirus using an electron microscope and compiled the images to reveal the structure of the virus.
In light of the COVID-19 pandemic, the creators of the Clinical Research Navigator (CRN) tool have offered free access to their system for biomedical researchers.
Researchers have used high-throughput screening to discover the best combinations of purified cannabinoids against gastrointestinal cancer cells.
Researchers have optimised PROTAC substances to degrade and dispose of proteins that support cancers, by customising their structure and selecting the best ligases.
A molecule called BOLD-100, developed to fight cancer, has been suggested as a therapeutic to combat the COVID-19 coronavirus due to its antiviral properties.
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.
The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains. Here, Joseph Steward highlights key findings of recent research.
Several new advances have been made in the field of drug discovery for diabetes – here, three of the most recent have been rounded up.